Update and future of systemic acne treatment

Dermatology

Volumn 206, Issue 1, 2003, Pages 37-53

  Zouboulis, Christos C ^a   Piquero Martin, Jaime ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b INSTITUTO DE BIOMEDICINA   (Venezuela)

Author keywords

Acne; Future; Review; Therapy; Update

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AZITHROMYCIN; BENZOYL PEROXIDE; CHLORMADINONE ACETATE; CIMETIDINE; CLINDAMYCIN; CYPROTERONE ACETATE; DESOGESTREL; DEXAMETHASONE; DOXYCYCLINE; DROSPIRENONE; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUTAMIDE; ISOTRETINOIN; KETOCONAZOLE; LEVONORGESTREL; LIPOXYGENASE INHIBITOR; LYMECYCLINE; MINOCYCLINE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; OXYTETRACYCLINE; PREDNISOLONE; PREDNISONE; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TETRACYCLINE; UNINDEXED DRUG;

ACNE FULMINANS; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ATAXIA; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BREAST TENDERNESS; CALCIFICATION; CHEILITIS; CONFERENCE PAPER; CONGENITAL MALFORMATION; CONJUNCTIVITIS; DERMATITIS; DESQUAMATION; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRY SKIN; EDEMA; EOSINOPHILIA; EPISTAXIS; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEPATITIS; HIRSUTISM; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPEROSTOSIS; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; INCREASED APPETITE; INTERSTITIAL NEPHRITIS; INTRACRANIAL HYPERTENSION; KERATINIZATION; LIBIDO DISORDER; LIVER FAILURE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; MALE TYPE ALOPECIA; MENSTRUATION DISORDER; MYALGIA; PHOTOSENSITIVITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; PSEUDOMEMBRANOUS COLITIS; PUBERTY; RETINOL INTOXICATION; SEBORRHEA; SIDE EFFECT; SKIN ATROPHY; SKIN DISCOLORATION; SKIN MANIFESTATION; SPONTANEOUS ABORTION; THROMBOSIS; TOOTH COLOR; TREATMENT OUTCOME; VERTIGO; VESTIBULAR DISORDER; WEIGHT GAIN; XEROSIS;

ACNE VULGARIS; ADMINISTRATION, ORAL; ANDROGEN ANTAGONISTS; ANTI-BACTERIAL AGENTS; CHEILITIS; CLINDAMYCIN; CYPROTERONE; FORECASTING; HUMANS; ISOTRETINOIN; SEVERITY OF ILLNESS INDEX; TETRACYCLINES;

EID: 0037260102     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067821     Document Type: Conference Paper

References (125)

1. Gollnick H, Zouboulis ChC, Akamatsu H, Kurokawa I, Schulte A: Pathogenesis and pathogenesis related treatment of acne. J Dermatol 1991;18:489-499.
2. Brown SK, Shalita AR: Acne vulgaris. Lancet 1998;351:1871-1876.
3. Zouboulis ChC: Acne: Current aspects on pathology and treatment. Dermatol Experiences 1999;1:6-37.
4. Piquero-Martín J: Acné - Manejo racional, ed 3. Caracas, Corpográfica, 2000.
5. Cunliffe WJ, Eady EA: A reappraisal and update on the pathogenesis and treatment of acne. Cur Opin Infect Dis 1992;5:703-710.
6. Dreno B, Poli F: Epidemiology of acne. Dermatology 2003;206:7-10.
7. Stern R: Medication and medical service utilization for acne 1995-1998. J Am Acad Dermatol 2000;43:1042-1048.
8. Leyden JJ: Therapy for acne vulgaris. N Engl J Med 1997;336:1156-1162.
9. Green J, Sinclair RD: Perceptions of acne vulgaris in final year medical student written examination answers. Austr J Dermatol 2001;42: 98-101.
10. Zouboulis ChC, Fimmel S, Ortmann J, Turnbull JR, Boschnakow A: Sebaceous glands; in Hoath SB, Maibach H (eds): Neonatal Skin -Structure and Function, ed 2. New York, Marcel Dekker, in press.
11. Cunliffe WJ, Holland DB, Clark SM, Stables GI: Comedogenesis: Some new aetiological, clinical and therapeutic strategies. Dermatology 2003;206:11-16.
12. Eady EA, Gloor M, Leyden JJ: Propionibacterium acnes resistance: A world wide problem. Dermatology 2003;206:54-56.
13. Zouboulis ChC: Is acne vulgaris a genuine inflammatory disease? Dermatology 2001;203: 277-279.
14. Herane MI, Ando I: Acne in infancy and acne genetics. Dermatology 2003;206:24-28.
15. Zouboulis ChC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, Scherbaum WA, Orfanos CE, McCann SM, Bornstein SR: Corticotropin releasing hormone: An autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci USA 2002;99: 7148-7153.
16. Toyoda M, Morohashi M: New aspects in acne inflammation. Dermatology 2003;206:17-23.
17. O'Brien SC, Lewis JB, Cunliffe WJ: The Leeds revised acne grading system. J Dermatol Treat 1998;9:215-220.
18. Pochi PE, Shalita AR, Strauss JS, Webster SB, Cunliffe WJ, Katz HI, Kligman AM, Leyden JJ, Lookingbill DP, Plewig G, et al: Report of the consensus conference on acne classification. J Am Acad Dermatol 1991;24:495-500.
19. Cunliffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, Gollnick H, Layton AM, Leyden JJ, Mascaro JM, Ortonne JP, Shalita A: Roaccutane treatment guidelines: Results of an international survey. Dermatology 1997;194:351-357.
20. Orfanos CE, Adler YD, Zouboulis ChC: The SAHA syndrome. Horm Res 2000;54:251-258.
21. Thiboutot DM: Endocrinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol 2001; 15(suppl 3):57-61.
22. Madden WS, Landells ID, Poulin Y, Searles GE, Smith KC, Tan JK, Toole J, Zip CM, Degreef H: Treatment of acne vulgaris and prevention of acne scarring: Canadian consensus guidelines. J Cutan Med Surg 2000;4(suppl 1): S2-13.
23. Slayden SM, Moran C, Sams WM Jr, Boots LR, Azziz R: Hyperandrogenemia in patients presenting with acne. Fertil Steril 2001;75:889-892.
24. Zouboulis ChC: Human skin: An independent peripheral endocrine organ. Horm Res 2000; 54:230-242.
25. Thiboutot D, Chen W: Update and future of hormonal therapy in acne. Dermatology 2003; 206:56-67.
26. Chen W, Thiboutot D, Zouboulis ChC: Cutaneous androgen metabolism: Basic research and clinical perspectives. J Invest Dermatol, in press.
27. Shaw JC: Hormonal therapies in acne. Expert Opin Pharmacother 2002;3:865-874.
28. Orfanos CE, Zouboulis ChC: Oral retinoids in the treatment of seborrhoea and acne. Dermatology 1998;196:140-147.
29. Zouboulis ChC, Korge B, Akamatsu H, Xia L, Schiller S, Gollnick H, Orfanos CE: Effects of 13-cis-retinoic acid, all-trans-retinoic acid and acitretin on the proliferation, lipid synthesis and keratin expression of cultured human sebocytes in vitro. J Invest Dermatol 1991;96: 792-797.
30. Gollnick H: Topical treatment in acne: Current status and future aspects. Dermatology 2003; 206:29-36.
31. Kaminsky A: Less common methods to treat acne. Dermatology 2003;206:68-73.
32. Toyoda M, Morohashi M: An overview of topical antibiotics for acne treatment. Dermatology 1998;196:130-134.
33. Meynadier J, Alirezai M: Systemic antibiotics for acne. Dermatology 1998;196:135-139.
34. Chen Q, Koga T, Uchi H, Hara H, Terao H, Moroi Y, Urabe K, Furue M: Propionibacterium acnes-induced IL-8 production may be mediated by NF-kappaB activation in human monocytes. J Dermatol Sci 2002;29:97-103.
35. Sykes NL Jr, Webster GF: Acne. A review of optimum treatment. Drugs 1994;48:59-70.
36. Holland KT, Aldana O, Bojar RA, Cunliffe WJ, Eady EA, Holland DB, Ingham E, McGeown C, Till A, Walters C: Propionibacterium acnes and acne. Dermatology 1998;196: 67-68.
37. Akamatsu H, Tomita T, Horio T: Effects of roxithromycin on the production of lipase and neutrophil chemotactic factor by Propionibacterium acnes. Dermatology 2002;204:277-280.
38. Leyden JJ: Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 2001;15(suppl 3):51-55.
39. Chosidow O, Poli F, Naline E, Advenier C, Revuz J: Comedonal diffusion of minocycline in acne. Dermatology 1998;196:162.
40. Colvin JH, Sheth AP: Minocycline hypersensitivity syndrome with hypotension mimicking septic shock. Pediatr Dermatol 2001;18:295-298.
41. Kiessling S, Forrest K, Moscow J, Gewirtz A, Jackson E, Roszman T, Goebel J: Interstitial nephritis, hepatic failure, and systemic eosinophilia after minocycline treatment. Am J Kidney Dis 2001;38:E36.
42. Seaman HE, Lawrenson RA, Williams TJ, MacRae KD, Farmer RD: The risk of liver damage associated with minocycline: A comparative study. J Clin Pharmacol 2001;41:852-860.
43. Balestrero S, Ciambellotti A, Parodi A, Rebora A: Minocycline-induced lupus-like syndrome. Int J Dermatol 2001;40:474-475.
44. Hughes BR, Murphy C, Barnett J, Cunliffe WJ: Strategy of acne therapy with long-term antibiotics. Br J Dermatol 1989;121:623-628.
45. Berson DS, Shalita AR: The treatment of acne: The role of combination therapies. J Am Acad Dermatol 1995;32:S31-S41.
46. Gollnick HP, Graupe K, Zaumseil RP: Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001;11:538-544.
47. Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H, Exner JH: Isotretinoin therapy for acne: Results of a multicenter dose-response study. J Am Acad Dermatol 1984;10: 490-496.
48. Layton AM, Knaggs H, Taylor J, Cunliffe WJ: Isotretinoin for acne vulgaris -10 years later: A safe and successful treatment. Br J Dermatol 1993;129:292-296.
49. Lehucher-Cheyrac DS, Weber-Buisset MJ: Isotretinoin and acne in practice: A prospective analysis of 188 cases over 9 years. Dermatology 1993;186:123-128.
50. Piquero Martín J, Urdaneta N: Experiencia clínica del Isotretinoín en acné, Rosácea e Hidradenitis. Derm Venez 1987;25:35-40.
51. Leyden JJ, McGinley KJ, Foglia AN: Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J Invest Dermatol 1986;86:390-393.
52. Chivot M, Midoun H: Isotretinoin and acne: A study of relapses. Dermatologica 1990;180: 240-243.
53. Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ: Isotretinoin for the treatment of acne vulgaris: Which factors may predict the need for more than one course? Br J Dermatol 1993; 129:297-301.
54. Karvonen SJ: Acne fulminans. Report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993;28:572-579.
55. Cunliffe WJ, Layton AM: Oral isotretinoin: Patient selection and management. J Dermatol Treat 1993;4(suppl 2):S10-S15.
56. Dai WS, LaBraico JM, Stern RS: Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992;26:599-606.
57. Mitchell AA, Van Bennekom CM, Louik C: A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995;333:101-106.
58. Altman RS, Altman LJ, Altman JS: A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology 2002;204:232-235.
59. Margolis DJ, Attie M, Leyden JJ: Effects of iso-tretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Arch Dermatol 1996;132:769-774.
60. Shaw JC: Antiandrogen and hormonal treatment of acne. Dermatol Clin 1996;4:803-811.
61. Beylot C, Doutre MS, Beylot-Barry M: Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology 1998;196: 148-152.
62. Piquero Martin J, Acosta H: Uso de acetato de ciproterona en el tratamiento del acné. Med Cutan Ibero Lat Am 1982;10:261-266.
63. Carmina E, Lobo RA: A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf) 2002;57:231-234.
64. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R: The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69(suppl):2-15.
65. Vartiainen M, de Gezelle H, Broekmeulen CJ: Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care 2001;6:46-53.
66. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N: Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/ LNG (Microgynon). Dermatology 2001;203: 38-44.
67. Thiboutot D: Acne and rosacea: New and emerging therapies. Dermatol Clin 2000;18: 63-71.
68. Brache V, Faundes A, Alvarez F, Cochon L: Nonmenstrual adverse events during use of implantable contraceptives for women: Data from clinical trials. Contraception 2002;65:63-74.
69. Lubbos HG, Hasinski S, Rose LI, Pollock J: Adverse effects of spironolactone therapy in women with acne. Arch Dermatol 1998;134: 1162-1163.
70. Schmidt JB: Other antiandrogens. Dermatology 1998;196:153-157.
71. Dodin S, Faure N, Cedrin I, Mechain C, Turcot-Lemay L, Guy J, Lemay A: Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin Endocrinol (Oxf) 1995;43:578-582.
72. Seukeran DC, Cunliffe WJ: The treatment of acne fulminans: A review of 25 cases. Br J Dermatol 1999;141:307-309.
73. Bass D, Zouboulis ChC: Behandlung der Acne fulminans mit Isotretinoin und Prednisolon. Z Hautkr 2001;76:473.
74. Vexiau P, Baspeyras M, Chaspoux C, Foin N, Allaert FA, Abramovici Y: Acne in adult women: data from a national study on the relationship between type of acne and markers of clinical hyperandrogenism. Ann Dermatol Venereol 2002;129:174-178.
75. Bradlow HL, Murphy J, Byrne JJ: Immunological properties of dehydroepiandrosterone, its conjugates, and metabolites. Ann NY Acad Sci 1999;876:91-101.
76. Honeyman J: Isotretinoína oral en dosis bajas en el tratamiento del acné moderado. Dermatol Argent 1998;4:338-344.
77. Goulden V, Clark SM, McGeown C, Cunliffe WJ: Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997;137:106-108.
78. Palmer RA, Sidhu S, Goodwin PG: 'Micro-dose' isotretinoin. Br J Dermatol 2000;143: 205-206.
79. Seukeran DC: Acne vulgaris in the elderly: The response to low dose isotretinoin. Br J Dermatol 1998,139:99-101.
80. Piquero-Martin J, Misticone S, Piquero-Casals V, Piquero-Casals J: Topic therapy-mini isotretinoin doses vs topic therapy-systemic antibiotics in the moderate acne patients. Ann Dermatol Venereol 2002;129:S382.
81. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, Lowe NJ, Jones TM, Stewart DM, Jarratt MT, Katz I, Pariser DM, Pariser RJ, Tschen E, Chalker DK, Rafal ES, Savin RP, Roth HL, Chang LK, Baginski DJ, Kempers S, McLane J, Eberhardt D, Leach EE, Bryce G, Hong J: A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol 2001;45:187-195.
82. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, Lowe NJ, Jones TM, Stewart DM, Jarratt MT, Katz I, Pariser DM, Pariser RJ, Tschen E, Chalker DK, Rafal ES, Savin RP, Roth HL, Chang LK, Baginski DJ, Kempers S, McLane J, Eberhardt D, Leach EE, Bryce G, Hong J: Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 2001;45:196-207.
83. Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, Lovey A, Kastner P, Grippo JF, Chambon P, et al: Retinoic acid receptors and retinoid X receptors: Interactions with endogenous retinoic acids. Proc Natl Acad Sci USA 1993;90:30-34.
84. Sitzmann JH, Bauer FW, Cunliffe WJ, Holland DB, Lemotte PK: In situ 13-cis-hybridization analysis of CRABP II expression in sebaceous follicles from retinoic acid-treated acne patients. Br J Dermatol 1995;133:241-248.
85. Tsukada M, Schröder M, Roos TC, Chandraratna RAS, Reichert U, Merk HF, Orfanos CE, Zouboulis ChC: 13-cisRetinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol 2000;115:321-327.
86. Tsukada M, Schröder M, Seltmann H, Orfanos CE, Zouboulis ChC: High albumin levels restrict the kinetics of 13-cisretinoic acid uptake and intracellular isomerization to all-transretinoic acid and inhibit its anti-proliferative effect on SZ95 sebocytes. J Invest Dermatol 2002; 119:182-185.
87. Jacobs DG, Deutsch NL, Brewer M: Suicide, depression, and isotretinoin: Is there a causal link? J Am Acad Dermatol 2001;45:S168-S175.
88. Fraunfelder FT, Fraunfelder FW, Edwards R: Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001;132: 299-305.
89. Pierard-Franchimont C, Goffin V, Arrese JE, Martalo O, Braham C, Slachmuylders P, Pierard GE: Lymecycline and minocycline in inflammatory acne: A randomized, double-blind intent-to-treat study on clinical and in vivo antibacterial efficacy. Skin Pharmacol Appl Skin Physiol 2002;15:112-119.
90. Akamatsu H, Horio T: Concentration of roxithromycin in the lesions of acne vulgaris. J Int Med Res 2001;29:537-540.
91. Akamatsu H, Tomita T, Horio T: Effects of roxithromycin on the production of lipase and neutrophil chemotactic factor by Propionibacterium acnes. Dermatology 2002;204:277-280.
92. Inui S, Nakajima T, Fukuzato Y, Fujimoto N, Chang C, Yoshikawa K, Itami S: Potential anti-androgenic activity of roxithromycin in skin. J Dermatol Sci 2001;27:147-151.
93. Parsad D, Pandhi R, Nagpal R, Negi KS: Azithromycin monthly pulse vs daily doxycycline in the treatment of acne vulgaris. J Dermatol 2001;28:1-4.
94. Kawada A, Aragane Y, Tezuka T: Levofloxacin is effective for inflammatory acne and achieves high levels in the lesions: An open study. Dermatology 2002;204:301-302.
95. Soto P, Cunliffe W, Meynadier J, Alirezai M, George S, Couttes I, Roseeuw D, Briantais P: Efficacy and safety of combined treatment of acne vulgaris with adapalane and lymecycline. Ann Dermatol Venereol 2002;129:1S602.
96. Lemay A, Dewailly SD, Grenier R, Huard J: Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metabolism 1990;71:8-14.
97. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD: A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microgram of levonorgestrel for acne treatment. Fertil Steril 2001;76:461-468.
98. Vree ML, Schmidt J: A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany. Eur J Contracept Reprod Health Care 2001;6:108-114.
99. Maloney M, Arbit D, Flack M, McLaughlin-Miley C, Sevilla C, Derman R: Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Women's Hlth 2001;1:124-131.
100. Lucky A, Henderson T, Olson W, Robisch D, Lebwohl M, Swinyer L: Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-754.
101. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL: Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-622.
102. Burkhart CG, Cantrill J, Butcher CL, Lehmann PF. Propionibacterium acnes: Interaction with complement and development of an enzyme-linked immunoassay for the detection of antibody. Int J Dermatol 1999;38: 200-203.
103. Ingham E, Eady EA, Goodwin CE, Cove JH, Cunliffe WJ. Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992;98:895-901.
104. Antilla HS, Reitamo S, Saurat JH: Interleukin 1 immunoreactivity in sebaceous glands. Br J Dermatol 1992;127:585-588.
105. Boehm KD, Yun JK, Strohl KP, Elmets CA: Messenger RNAs for the multifunctional cytokines interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor-alpha are present in adnexal tissues and in dermis of normal human skin. Exp Dermatol 1995;4: 335-341.
106. Vowels BR, Yang S, Leyden JJ: Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: Implications for chronic inflammation acne. Infect Immun 1995;63:3158-3165.
107. Guy R, Green MR, Kealey T: Modeling acne in vitro. J Invest Dermatol 1996;106:176-182.
108. Seltmann H, Oeff M, Zouboulis ChC: CD14 expression in human sebocytes and IL8 regulation by lipopolysaccharides, phorbol myristate acetate and linoleic acid. Arch Dermatol Res 2002;294:33.
109. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, Brightbill HD, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL: Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002;169: 1535-1541.
110. Oeff MK, Seltmann H, Hakiy N, Bogdanoff B, Nastos A, Walters R, Bornstein SR, Zouboulis ChC: Toll-like receptor 2 and 4-dependent regulation of inflammatory signaling in human sebocytes. J Invest Dermatol 2002; 119:736.
111. Crooks SW, Stockley RA: Leukotriene B4. Int J Biochem Cell Biol 1998;30:173-178.
112. Zouboulis ChC: Exploration of retinoid activity and the role of inflammation in acne: Issues affecting future directions for acne therapy. J Eur Acad Dermatol Venereol 2001; 15(suppl 3):63-67.
113. Wozel G, Chang A, Zultak M, et al: The effect of topical retinoids on the leukotriene-B4-induced migration of polymorphonuclear leu-kocytes into human skin. Arch Dermatol Res 1991;283:158-161.
114. Berbis Ph: L'isotrétinoîne est-elle pro ou anti-inflammatoire? Ann Dermatol Venereol 2001;128:2S25-2S28.
115. Zouboulis ChC, Oeff KM, Seltmann H, Walters RJ, Nastos A, Bornstein SR: Differential modulation of CD14 expression in sebocytes by retinoids. Arch Dermatol Res 2002;294: 48.
116. Kang S: Current perspectives on acne inflammation and scarring. Ann Dermatol Venereol 2002;129:1S190.
117. Pugeat M, Ducluzeau PH: Insulin resistance, polycystic ovary syndrome and metformin. Drugs 1999;58(suppl 1):41-46; discussion 75-82.
118. Smith KJ, Dipreta E, Skelton H: Peroxisomes in dermatology. Part I. J Cutan Med Surg 2001;5:231-243.
119. Rosenfield RL, Kentsis A, Deplewski D, Ciletti N: Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors. J Invest Dermatol 1999;112:226-232.
120. Chen W-C, Zouboulis ChC, Orfanos CE: The 5α-reductase system and its inhibitors; recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996;193:177-184.
121. Cilotti A, Danza G, Serio M: Clinical application of 5alpha-reductase inhibitors. J Endocrinol Invest 2001;24:199-203.
122. Chen W, Zouboulis ChC, Fritsch M, Blume-Peytavi U, Kodelja V, Goerdt S, Luu-The V, Orfanos CE: Evidence of heterogeneity and quantitative differences of the type 1 5α-reductase expression in cultured human skin cells: Evidence of its presence in melanocytes. J Invest Dermatol 1998;110:84-89.
123. Fritsch M, Orfanos CE, Zouboulis ChC: Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 2001;116:793-800.
124. Fimmel S, Saborowski A, Bogdanoff B, Orfanos CE, Zouboulis ChC: Inhibition of androgen receptor expression and of androgen activity on human sebocytes by antisense oligo-nucleotides. Ann Dermatol Venereol 2002; 129:1S375.
125. Cunliffe WJ: Looking back to the future -Acne. The first William J. Cunliffe Lecture. Dermatology 2002;204:167-172.